Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of “Moderate Buy” by Brokerages

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $44.2857.

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Guggenheim increased their price target on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, March 16th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Finally, Zacks Research raised shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th.

Insiders Place Their Bets

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the business’s stock in a transaction on Monday, May 18th. The stock was bought at an average price of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the purchase, the chief executive officer directly owned 96,928 shares in the company, valued at $1,636,144.64. The trade was a 162.48% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders purchased 120,000 shares of company stock valued at $2,080,000 in the last ninety days. Corporate insiders own 22.00% of the company’s stock.

Hedge Funds Weigh In On Zenas BioPharma

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Zenas BioPharma by 25.0% in the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after buying an additional 290,307 shares during the period. EcoR1 Capital LLC purchased a new position in Zenas BioPharma in the fourth quarter worth approximately $28,667,000. NEXTBio Capital Management LP purchased a new position in Zenas BioPharma in the fourth quarter worth approximately $11,691,000. Polar Capital Holdings Plc acquired a new position in Zenas BioPharma during the 4th quarter worth approximately $38,402,000. Finally, iA Global Asset Management Inc. acquired a new position in Zenas BioPharma during the 1st quarter worth approximately $4,219,000.

Zenas BioPharma Stock Performance

NASDAQ ZBIO opened at $27.23 on Friday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94. The stock’s fifty day moving average is $19.90 and its two-hundred day moving average is $23.00. The firm has a market capitalization of $1.72 billion, a P/E ratio of -3.21 and a beta of -0.96. Zenas BioPharma has a fifty-two week low of $9.21 and a fifty-two week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. During the same period last year, the company earned ($0.80) earnings per share. On average, research analysts anticipate that Zenas BioPharma will post -4.47 earnings per share for the current year.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.